Notice Regarding Regulatory Approval of China WOMA’s Locally Manufactured “Artificial Hip Joint Products” and Commencement of Sales in the Chinese Market

Plan to Comply with the Listing Maintenance Criteria (Market Capitalization of Tradable Shares), Including the Initiation of an Improvement Period and Consideration or Applic

Notice Regarding Differences Between the Full-Year Consolidated Financial Forecast for the FYE March 31, 2026 and the Actual Results

Notice-Regarding-Transition-to-Company-with-Audit-and-Supervisory-Committee-Change-in-Method-of-Public-Notice-and-Partial-Amendments-to-the-Articles-of-Incorporation

Notice-Regarding-Personnel-Appointments-for-Directors-Director-and-Audit-Committee-Member-and-Executive-Officers

Notice-Regarding-the-Resignation-of-an-Auditor-and-the-Change-in-Full-Time-Auditors

Notice Regarding Revision of Consolidated Earnings Forecasts for the Full Year of the FYE March 31 2026

Notice Regarding Revision of Consolidated Earnings Forecasts for the Second Quarter of the Fiscal Year Ending March 31, 2026, and Revision of Consolidated Earnings Forecasts for the Full Year of the Fiscal Year Ending March 31, 2026

Matters Concerning Controlling Shareholders, etc.

Notice Regarding Differences between Full-Year Consolidated Financial Forecasts and Actual Results for the Fiscal Year Ended March 2025